by The global Hodgkins Lymphoma Treatment Market is estimated to be valued at US$ 0.59 Bn in 2023 and is expected to exhibit a CAGR of 11.% over the forecast period 2023 to 2030, as highlighted in a new report published by Coherent Market Insights.
Market Overview
Hodgkin’s lymphoma is a type of lymphoma which involves cancerous changes in the lymphatic system. Most commonly used treatment includes chemotherapy, radiation therapy, stem cell transplant which helps in effectively killing cancerous cells.
Market key trends
One of the key trends in the market is rising investment in R&D activities focused on development of targeted therapies. Major players are increasingly investing in development of new targeted therapies such as antibody drug conjugates (ADCs), bispecific antibodies, and checkpoint inhibitors etc. which specifically targets Hodgkin’s lymphoma cells and have fewer side effects compared to traditional chemotherapy. For instance, in 2021, FDA approved Polivy (polatuzumab vedotin-piiq) in combination with bendamustine plus Rituxan for relapsed or refractory DLBCL.
SWOT Analysis
Strength: Hodgkins lymphoma treatment is highly responsive to chemotherapy. Modern combination chemotherapy regimens cure over 80% of patients.
Weakness: Chemotherapy treatment comes with risk of severe side effects. Relapse after treatment is also a concern.
Opportunity: Advancements in targeted therapies and immunotherapies offer new treatment options with improved safety profiles. Recent drug approvals have expanded treatment landscape.
Threats: High cost of new targeted drugs can limit their accessibility. Long-term toxicities of chemotherapy are still an issue.
Key Takeaways
The global Hodgkins Lymphoma Treatment Market Size is expected to witness high growth, exhibiting a CAGR of 11% over the forecast period, due to increasing approval and adoption of newer targeted and immune-oncology drugs.
North America is expected to dominate the global Hodgkins lymphoma treatment market during the forecast period. High awareness regarding cancer, well-developed healthcare infrastructure, and strong presence of market leaders are some factors supporting market growth in the region. Asia Pacific is anticipated to exhibit fastest growth over the forecast period due to rising healthcare expenditure and increasing diagnoses.
Key players operating in the Hodgkins lymphoma treatment market are Bristol Myers Squibb, Johnson & Johnson, AbbVie Inc., and Merck & Co., Inc. These players are focused on developing novel targeted and immune-oncology-based treatment options.
*Note:
1. Source: Coherent Market Insights, Public sources, Desk research
2. We have leveraged AI tools to mine information and compile it
